First results of the Phase II TITAN trial: anti-von Willebrand ... - Ablynx

02.03.2013 • Views

Share Embed Flag

First results of the Phase II TITAN trial: anti-von Willebrand ... - Ablynx

First results of the Phase II TITAN trial: anti-von Willebrand ... - Ablynx

DOWNLOAD ePAPER

ablynx.com

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

START NOW

Preliminary observations: RiCo (n = 5/110)<br />

Normal range<br />

25

1/29 N/MDP/ Ablynx Ablynx Naamloze vennootschap ...

Routebeschrijving naar Ablynx

ABLYNX VOLTOOIT ZIJN €40 MILJOEN (~US$50 MILJOEN) SERIE ...

Press release of 25 March 2010 - Ablynx

The Discovery of anti-IL-6R Nanobodies® - Ablynx

Nanobodies - Ablynx

R&D Review Day 2012 - Ablynx

Nanobodies® – a unique product engine - Ablynx

Nanobodies® – de nieuwe generatie geneesmiddelen - Ablynx

Nanobodies® – a unique product engine - Ablynx

Preliminary observations: platelet count (n = 5/110) 24

Preliminary observations: RiCo (n = 5/110) Normal range 25

Page 1 and 2: First results of the Phase II TITAN
Page 3 and 4: Clinical symptoms at the first thre
Page 5 and 6: ADAMTS13 • VWF cleaving protease
Page 7 and 8: Treatment of acute TTP • Survival
Page 9 and 10: Immunosuppressive agents • Cortic
Page 11 and 12: Perspectives • Recombinant ADAMTS
Page 13 and 14: ALX-0081: mode of action in TTP •
Page 15 and 16: ALX-0081 potently neutralises ULVWF
Page 17 and 18: The TITAN trial: study design Inclu
Page 19 and 20: Nanobodies ® - Inspired by nature
Page 21 and 22: Demographic and baseline characteri
Page 23: PE details • PE treatment - varia
Page 27 and 28: Preliminary observations: FVIII aci
Page 29 and 30: Preliminary observations: anti-ADAM
Page 31 and 32: Serious adverse events • 2 SAEs r
Page 33: Acknowledgements • Hemophilia and